Suchergebnisse - "Foulon, Stéphanie"

PubPharm (43)

1

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel : The PACAP Study

enthalten in: European urology oncology | 2024

von Flippot, R. | Telli, T. | Velev, M. | +26

2

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer : Patient Preference and Cognitive Function in ODENZA

enthalten in: European urology | 2024

von Colomba, E. | Jonas, S. | Eymard, J. | +21

3

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

enthalten in: Cancers | 2022

von Wysocki, O. | Zhou, C. | Rogado, J. | +72

4

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

enthalten in: JCO clinical cancer informatics | 2022

von Lee, R. | Wysocki, O. | Zhou, C. | +75

5

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1) : a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

enthalten in: Lancet (London, England) | 2022

von Fizazi, K. | Foulon, S. | Carles, J. | +31

CommentIn: Lancet. 2022 Apr 30;399(10336):1670-1671. - PMID 35405082

6

What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

enthalten in: Journal of neuro-oncology | 2021

von Adelon, J. | Dufour, C. | Foulon, S. | +14

7

Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5

enthalten in: Neuro-oncology | 2021

von Dufour, C. | Foulon, S. | Geoffray, A. | +21

CommentIn: Neuro Oncol. 2021 Jul 1;23(7):1048-1049. - PMID 33903906

8

What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

enthalten in: Journal of neuro-oncology | 2021

von Adelon, J. | Dufour, C. | Foulon, S. | +14

9

What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

enthalten in: Journal of neuro-oncology | 2021

von Adelon, J. | Dufour, C. | Foulon, S. | +14

10

What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

enthalten in: Journal of neuro-oncology | 2021

von Adelon, J. | Dufour, C. | Foulon, S. | +14

1
2
3
4
5
Nächster »
[5]